Nalaganje...
Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
The development of radiolabeled antibodies against CD20 has facilitated targeted treatment of follicular lymphoma (FL). By using (90)Y-ibritumomab tiuxetan (Zevalin(®)), a radionuclide (yttrium-90, linked by the chelator tiuxetan to the antibody ibritumomab) is brought into the vicinity of lymphoma...
Shranjeno v:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2009
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2886339/ https://ncbi.nlm.nih.gov/pubmed/20616907 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|